Agenda

Agenda

Download the Brochure

General Session

Monday, October 24
7:00 Breakfast
8:00

Opening Remarks: Todd Eury, Pharmacy Podcast Network

8:30

 

Panel: The Unlimited Opportunities of Entrepreneurial Practice of Pharmacy

  • Panel of pharmacy influencers share their thoughts on this topic and keynote address

9:15

 

Fireside Chat – Creating Protocols for Effective Treatment Of Disorders Effecting the Brain

  • How this came about; Treating Vets with traumatic brain injuries and ptsd – case study
  • Demonstrate applications that can be applied to a wide variety of issues affecting literally every family in the U.S.
  • Explore practice types and groups that could employ these protocols
10:00

RX Impact Idea: The power of Vision and Values for the Entrepreneur
Melissa Myers, Wealth Manager-The Melissa Myers Group

10:00 Break – move into individual tracks
 
Day 2: October 25
7:00 Breakfast
8:00 Recap of Day 1
8:00  Opening Remarks, Recap of Day 1
8:15

RX Impact Idea – The Death of the Medical Cannabis Product, Jason S Nelson, COO, BeLeaf Medical

9:15

Fireside chat: Proving Opiate Reduction Using Cannabis

10:00

RX Impact Idea – Jena Quinn, PharmD, BCPPS, Owner, Perfecting Peds

10:15 Break – move into individual tracks

Growth & Entrepreneurship

Tuesday, October 25
12:30 Special Event: Financial Planning for Women Pharmacists with Melissa Myers
1:30

Panel: To B or not to B, that is the decade long question. 503A – B?

  • Can I partner with a 503B?
  • What is the best and the worst state for 503B facilities?
  • Other than hospital work, what else can a 503B do?
  • How hard is it to get into the drug shortage business?
2:15

Activity: Your Dreams are URGENT! How to Move Forward in Life and Business

  • Dr. Jerrica Dodd, Pharmacist Coach, Executive Editor PharmaSis Magazine

Are you stuck?  Do you want to move forward in your life, become an entrepreneur, create new revenue streams for your business but find yourself unable to make any changes? Join Dr. Jerrica Dodd as she shares pearls and coaches on moving forward and building your dreams.

3:15 Break
3:45

How do you grow without a team?

  • How do you create a loyal working team?
  • Do you manage from top down or bottom up? What does that even mean?
  • Do you take the Tony Hseish approach? Or the Elon Musk
4:30

Round Tables:

1.      Lean Six Sigma, Syed Saleem DPh, MBA, Senior Director, NexGen Pharmaceuticals

2.      Team Building, Jena Quinn, PharmD, BCPPS, Owner, Perfecting Peds

3.      Financial Planning, Melissa Myers, CFP ®, Wealth Manager-The Melissa Myers Group

5:00 End of Conference Day 1

 

Tuesday, October 25
10:45

Niche Idea, New Ideas, Nuevo Pharma, or “How about this?

  • Is basic compounding still viable?
  • Should I jump into PGX?
  • Is Cannabis an option for my pharmacy?
  • Is there a business in ophthalmology? Pediatrics? Geriatrics?
11:30 Round Tables:
 
  • Collaborative Practices – Rachael Pontikes, Partner, Reed Smith
  • Getting into Clinical Trials – Alexander Pytlarz, Pharmacist, President of Operations, Infuserve America
  • Pharma opportunities for pharmacists – Hetal Patel, PharmD, MBA, Medical Science Liaison
  • Specialized Markets – Greg McKettrick RPh, Compounding Pharmacist, Director of Business Development, Stanley Specialty Pharmacy
12:30 End Of Conference
2:00 Workshops begin

 

Compounding

 

Monday, October 24
10:45

Panel: Future of Compounding – Growth, Consolidation and New Opportunities

  • Examine if 503A consolidation is happening and should we be concerned
  • Review What opportunities are there for compounding pharmacies to increase revenue
  • Opportunities for 503Bs and 503As in supplements and micro-niche markets
11:30 Round Table Discussions (Visit 2 table topics during this hour)
 

1.      503B Inspections

  • Identify resources to prepare for an FDA inspection
  • Describe best practices for inspection readiness
  • Review most frequent 483’s

2.      503A Inspections

  • Review what FDA inspectors are permitted to inspect and, by law, what they are not permitted to inspect
  • Describe how staff should interact with FDA during the course of an inspection and the problems that pharmacy staff can experience when dealing with FDA inspectors in a high-stress situation
  • Describe how good documentation practices for everyday activities (such as cleaning) help your pharmacy respond to a Form FDA 483.

3.      DEA Inspections

  • Identify the role of DEA Diversion Control Division with regards to a 503A Compounder or a 503B Manufacturer
  • Review DEA required records to include compounding and DEA required records for controlled substances
  • The Due Diligence requirements of a 503A or 503B Compounder to prevent diversion of controlled substances

4.      503A Regulatory Update

5.      503B Regulatory Update

12:30 Special Event: Financial Planning for Women Pharmacists with Melissa Myers

1:30

 

Panel: Preventing Process Deviations in A Fluctuating Workforce

  • Explain why deviations are a big deal
  • Identify what causes of major deviations
  • Review what kind of deviations we are seeing
2:15 Round Tables (Visit 2 table topics during this hour)
 

1.      How to address opioid state fees

  • How many states do you currently pay the fees for?  Do you anticipate the number increasing?
  • Are the fees excessive for a 503B vs manufacturers?
  • DO you see value in lobbying to get these fees reduced?

2.      I’m Curious, How Do You Manage Workflow? Compare Systems from order Through Fulfillment

3.      Conducting Your Own Environmental Monitoring

  • List the essential components of performing your own viable air and surface sampling
  • Determine whether your organization wants to incubate and analyze the samples
  • Identify the training needs for conducting viable sampling and analyzing samples
3:15 Break

3:45

 

 

Fireside chat: Essentially A Copy – A Challenge for Both 503As and 503Bs

  • Understand what drugs need to be compounded from an API
  • Learn why? Is it primarily due to drug shortage or a clinical need?
  • Review how hospitals attest a clinical need to purchase 503B products?
  • Explore if the FDA drug shortage list accurately reflect shortages in the field?
  • Hypothesize for 503As what is the primary driver to compound from API?  Is it a patient specific prescription or a drug shortage or a specific presentation?
4:30 Round Tables
 

1.     Cited For What?! The Push For cGMP Like Rules and Standards in Sterile Facilities

2.      Creating a culture of compliance and audit readiness

  • Define compliance and non-conformance
  • Discuss daily habits/tasks to assure surprise audit readiness.
  • Review HOW TO PREPARE for customer audits!*

3.      503A Compliance

  • Identify the conflicts between USP 797 the FDA’s Insanitary Conditions Document
  • Explain how USP 797 compliance intersects USP 800 compliance
  • Evaluate your current operations for compliance opportunities

4.      Animals are not people (???)

  • Obtain pointers when compounding orders for the family dog or cat
  • Review the complexities around veterinary prescriptions
  • Outline references for veterinary clients – where can you find good information
5:00 End of Day 1 Conference

 

Tuesday, October 25

10:30

 

Panel: Retention and Hiring; Staff Development & Advancement

  • Learn ways to develop a culture that makes employees want to stay and resist poachers who offer more money
  • Gain an understanding of what millennials want in their job and their future
  • Identify ways to promote internally and recognize different types of leaders and the roles they can play in your organization
11:30 Round Tables (Visit 2 table topics during this hour)
 

1.      Poaching and staff retention

  • Illustrate a way of setting expectations for new employees
  • Describe how to create a culture that retains employees
  • Prepare HR for their role in hiring and keeping employee

2.      Navigating the complexities of state licensing for 503Bs

  • State licenses for 503B’s, outsourcing license, wholesale/distribution license, pharmacy license, manufacturing license?
  • Required FDA Inspections and the pandemic struggle
  • Disciplinary actions associated with FDA 483 Observations
  • Pharmacists license required in states

3.      503B Compliance

4.      Are you effectively moving technicians into leadership roles?

  • Identify all types of leaders and don’t expect them to be the same type of leaders – square pegs in square holes, round pegs in round holes
  • Prepare new managers for a different perspective then they had at their previous job
  • Solve problems of new leaders through effective training
12:30 End Of Conference
2:00 Workshops begin

 

Cannabis

 

Monday, October 24
10:45

Track Keynote – The History of Cannabis- Cannabis Introduction Topics

  • Discuss the cannabis plant and what it contains
  • Explain opportunities for pharmacies
  • Review where you can find Cannabinoid Education – Source
11:15

Panel: Discussion on Politics of Cannabis Treatment

  • Assess what will happen if cannabis become legal on a federal level
  • Managing an everchanging regulatory background
  • Obtaining scientific data to back up claims
  • Social equity outcomes
12:00 Round Tables: Learn more from the panelists, take a deeper dive and ask specific questions
12:30 Special Event: Financial Planning for Women Pharmacists with Melissa Myers

1:30

 

Panel: Utilizing Cannabis as A Therapy for Chronic Pain Management

  • Understand the difference and medical benefits of THC vs CBD
  • Learn how to identify effective off the shelf products
  • Examine established protocols for pain management and dosing
  • Address arguments against cannabis for pain management
2:15 Round Tables – (Visit 2 tables topics during this hour)
 

1.      Adverse Event Reporting

  • Why do we report ADRs?
  • What kinds of ADRs occur in the cannabis industry?
  • Potential/theoretical Drug Interactions
  • Questions that are important for establishing causality

2.      Building your auxiliary team

  • Identify types of Providers
  • Summarize types of Vetting
  • Analyze Partnerships & Marketing

3.      Different Q/A thresholds in different state markets

  • Initial and Current State of Q/A Testing
  • State to State Variance
  • Transition to a Consistent, Federally Regulated Q/A Testing Program

4.     Routes of Administration and Cannabis and Cannabinoids Dosing

3:15 Break

3:45

 

Regulatory Update: Hemp – 2018 US Farm Bill – Delta 8 THC, Delta 9 THC, Delta 10 THC

  • Review ways to talk to patients and medical professionals on differences between Delta 8, 9 and 10
  • Asses if there is a need for the different deltas being developed into specific and targeted applications
  • Identify a wish list of what policymakers should know about Delta 8, 9, and 10?
4:30 Round Table
 

1.      Exploring the science – ask your questions here

  •  Approved Cannabis “indications”
  • Clinical Conditions for which Cannabis is used
  • Cannabis Kinetics, routes of administration, dosage forms

2.      Interstate Commerce Implications

  •  Social equity implications
  • Variable batch testing requirements
  • Regulated market agreements

3.      Improving Patient Accessibility While Mitigating Black Market Appeal 

4.      How To Talk To A Doctor About Cannabis Usage

5:00 End of Conference Day 1

 

Tuesday, October 25
10:45

Panel: Risks to Patients that Need to Be Considered

  • Examine potential criminal, civil and employment consequences to patients when things go wrong
  • Review negative impact of THC and CBD on certain patient populations and how to avoid them
  • Examine potential interactions and side effects of medicines
11:30 Round Tables- (Visit 2 tables topics during this hour)
 

1.      Using Data from State Prescription Drug Management Program To Show Reduction On Opioid Use In Lieu Of Cannabis

2.      Fair Market Value of Pain Cream

3.      4th Year Rx Student APPE Clinical Rotation

  • Address the need for cannabis education in pharmacy schools
  • Discuss accessibility to cannabis APPE rotations
  • Comparison of dispensary set up and work flow vs traditional pharmacies
  • Express importance of pharmacists in dispensaries (medication therapy management)

4.      Improving patient relationships with practitioners

  • Setting proper expectations for treatment
  • Allocating proper time per patient
  • Having open access with your patients – pros and cons
12:30 End Of Conference
2:00 Workshops

Pharmacogenomics

Monday, October 24
10:45 Panel: Reviewing clinical data Is utilizing clinical judgment and looking at the overall patient
12:30 Special Event: Financial Planning for Women Pharmacists with Melissa Myers
1:30

Panel: Emerging Trends in Pharmacogenomics

  • Explore the increase in R&D and next-generation sequencing that will enable the establishment of effective strategies for discovering novel biomarkers associated with various diseases, which could be harnessed to develop targeted therapies.
  • Illustrate the increase in adoption of personalized medicine shifting the paradigm from reaction to prevention on a global level
  • Review regulatory challenges for direct-to-consumer (DTC) pharmacogenomics companies

 

3:45 Fireside Chat:  Role of Pharmacist in PGX And How to Take the Whole Patient into Account
5:00 End of Day 1

 

Tuesday, October 25
10:45 Panel: Opportunities (and challenges) To Whole Health Care Team Acceptance
11:30

1)     Maternal and pediatric: Jena Quinn, PharmD, BCPPS, Owner, Perfecting Peds

·        Resources for maternal health and pediatrics

·        How approach to a maternal/ fetal patient  

·        How to approach a pediatric patient

·        Pharmacogenomics in a Peds patient 

2)     Re-imbursement from managed care – Yana Vorontsova, Pharmacogenomics Program Leader, Nicklaus Children’s Health System

3)     Geriatric – Delon Canterbury, PharmD, BCGP, Chief Executive Officer, GeriatRx, Inc.

4)     Identifying A Population and Getting Grants – Corrie Sanders, Medication Safety Clinical Pharmacist, U.S. Department of Veterans Affairs Pacific Islands Healthcare System, President, Hawai’i Pharmacists Association (invited)

12:30 End Of Conference
2:00 Workshops begin

Workshops: October 25

Workshops are 2:00 – 4:30 with a 30-minute break at 3:00

How to Effectively Communicate Your SOPs –Bring Your Own SOP’s to Discuss – Abby Roth, Founder/Microbiologist, Pure Microbiology

  • Identify key elements for an effective SOP
  • Describe common SOP pitfalls and how to avoid them when drafting SOPs
  • Incorporate meaningful SOP training into the sterile compounding organization

Controlled Substances: What To Do or Know Before the DEA ArrivesCarlos Aquino, Compliance Consultant, Founder, Pharma Diversion LLC

  • Focus on DEA purpose for reviewing your DEA required records for controlled substances
  • Review the requirements to have an effect security program to guard against the diversion of controlled substances
  • Discuss the DEA “Know Your Customer” policy and their “Due Diligence” requirements of regulations

Who Should Attend

Quality Assurance

General Counsel

Quality Control

Pharmacy Services

Pharmacy Operations

Facilities Management

Owner / President / CEO

Supervising pharmacist or non-pharmacist manager equivalent

Compliance

Facility manager

Policy and Regulatory Affairs

Infection control lead

Legal

Process improvement

Industries

503A Pharmacies

503B Pharmacies

Hospital Pharmacies

Track Chairs

 

Growth and Alternative Revenue Streams

Dr. Jerrica Dodd

Dr. Jerrica Dodd

Founder/CEO Your Pharmacy Advocate, Executive Editor, PharmaSis Magazine

Compounding

Lou Diorio

Lou Diorio

Principal, LDT Health Solutions Inc

Cannabis

Joseph Friedman

Joseph Friedman

Medical Cannabis Pharmacology Expert/Advocate, CannaRPh Consultants LLC

Pharmacogenomics

Jamie Wilkey

Jamie Wilkey

co-Founder, PGx Accelerators

Speakers

 

Compounding

 

Varsha Gaitonde, PharmD, PhD, BCPS, BCSCP

Varsha Gaitonde, PharmD, PhD, BCPS, BCSCP

Vice President, Pharmacy Services, QuVa Pharma, Inc.

Session

CE, On Demand: 503B: Guidance on Essential Copies For 503Bs

In-Person: Essentially A Copy - A Challenge for Both 503A's and 503B's

 

Compounding

 

Wendy Hagwood

Wendy Hagwood

RPh, PIC, Ops Mgr at Triangle Compounding Pharmacy

Session

Round Table Moderator:  Animals are people too

 

 

Compounding

 

Peter Koshland

Peter Koshland

CEO, Koshland Pharm

Session

Poaching and staff retention

 

 

 

 

Compounding

Rachael Pontikes

Rachael Pontikes

Partner, Reed Smith LLP

Session

CE, On-Demand: Inspection Preparation & Response: During

In Person: 503A Regulatory Update

 

Compounding

Matthew R. Ludowig

Matthew R. Ludowig

Senior General Counsel, Empower Pharmacy

Session

in-person: Essentially A Copy - A Challenge for Both 503A's and 503B's

Compounding

Lee Rosebush

Lee Rosebush

Partner, BakerHostetler

Session

CE, On-Demand: Inspection Preparation & Response: Before

In-Person: 503B Regulatory Update

Compounding

Vicky A. Caldaro

Vicky A. Caldaro

Manager, Quality Operations , Immucor Inc.

Session

In-Person: Preventing Process Deviations in a Fluctuating Workforce

Compounding, Growth and Entrepreneurship

Syed Saleem DPh, MBA

Syed Saleem DPh, MBA

Senior Director, NexGen Pharmaceuticals

Session

CE, On-Demand: 503B: Qualifying Equipment With The Right Validations

In-Person: TBA

General Session, Compounding

Jim Hrncir RPh

Jim Hrncir RPh

Owner, Las Colinas Pharmacy Compounding

Session

Fireside chat: Creating Protocols for Effective Treatment Of Disorders Affecting the Brain

Panel: Future of Compounding – Growth, Consolidation and New Opportunities

Panel: Retention and Hiring; Staff Development & Advancement

Compounding, Cannabis

Karla L Palmer

Karla L Palmer

Director, Hyman Phelps & McNamara P.C.

Session

In-Person: Essentially a Copy, A Challenge for Both 503As and 503Bs

Compounding

Marc Wagner

Marc Wagner

Counsel, BakerHostetler

Session

Panel: 503B Regulatory Update

Round Table Moderator: 503B Inspections

Growth and Entrepreneurship, Cannabis

Greg McKettrick RPh

Greg McKettrick RPh

Compounding Pharmacist, Director of Business Development, Stanley Specialty Pharmacy

Session

In-Person: Success With Social Media - Increasing Your Customer Base Through Good Advice

Compounding, Workshop

 

Carlos M. Aquino

Carlos M. Aquino

Compliance Consultant, Founder, Pharma Diversion LLC

Session

CE, On-demand: Inspection Preparation & Response: DEA

In-Person: Round Table Moderator, DEA Inspections, Workshop - DEA Inspections

 

Compounding, Workshop

Abby Roth

Abby Roth

Owner/Microbiologist Pure Microbiology, LLC

Session

In-Person Workshop: Effectively writing and communicating SOP's

 

Compounding

Amy Summers PharmD, BCSCP

Amy Summers PharmD, BCSCP

Consultant, Restore Health Consulting

Session

Moderator: Preventing Process Deviations in A Fluctuating Workforce

Compounding, Growth and Entrepreneurship

Emily L. Hussey

Emily L. Hussey

Attorney, Reed Smith LLP.

Session

CE, On-Demand 503A: Creating a Testing Program

In-Person: TBD

Compounding

Pat	Stephens

Pat Stephens

Lead Consultant & Owner, Stephens Consulting

Session

503B Compliance:

Panel: Preventing Process Deviations in A Fluctuating Workforce

Growth and Entrepreneurship, Compounding

Alexander Pytlarz

Alexander Pytlarz

Pharmacist, President of Operations, Infuserve America

Session

Fireside chat: Retention and Hiring; Staff Development & Advancement

Growth and Alternative Revenue Streams: Round Table on getting involved in Clinical Trials

 

 

 

 

Compounding

Devin Wallace CPhT CSPT RPhT PRS

Devin Wallace CPhT CSPT RPhT PRS

Founder, CEO, Wallace Ventures

Session

Round Table moderator: Cited for what?! The push for CGMP like rules and standards in sterile facilities

Round Table: Are you effectively moving technicians into leadership roles

Compounding

Travis Leeah

Travis Leeah

Vice President Clinical Services and Pharmacist-in-Charge, QuVA Pharma

Session

Round table moderator: State licensing for 503B's

Round table moderator: How to address opioid state fees

 

Compounding

Jodi Peterson

Jodi Peterson

President/Owner, Precision Compounding Pharmacy

Session

Round Table: Marketing – Traditional and Social Media Campaigns, Efficacy, do’s and don’ts as learned on the fron

Fireside chat: Retention and Hiring; Staff Development & Advancement

 

 

 

 

Compounding

Robert Hopkins

Robert Hopkins

CFO, Empower Pharm

Session

503A: Relevant USP Chapters: Where to Find All the Information

Cannabis

Joe Jeffries

Joe Jeffries

Pharmacy Director, FarmaceuticalRx

Session
Fireside chat: using data from state prescription drug management program to show reduction on opioid use in lieu of cannabis

Cannabis

Becky Brown

Becky Brown

Doctor of Pharmacy Cannabis Educator & Coach Pharmedwell.com

Session

CE PRESENTER: Cannabis Pharmacology 101

ROUND TABLE MODERATOR: Building your external/auxiliary team

Cannabis

Jason S Nelson

Jason S Nelson

COO, Beleaf Medical

Session

Panel: Discussion on Politics of Cannabis Treatment

Round Table Moderator: Different Q/A thresholds in different state markets

 

Cannabis

James T. O'Donnell

James T. O'Donnell

President, Consultant, Pharma consultant Inc., Associate Professor, Rush Medical College

Session

Round Table: Exploring The Science – ask your questions here
Fireside Chat – Legal Risks To Users

Cannabis

Robert Morris

Robert Morris

Pharmacist, Beehive Farmacy

Session

Panel: Discussion on Politics of Cannabis Treatment
Round table: Routes of Administration and Cannabis and Cannabinoids Dosing

Cannabis

Erik	Bowen

Erik Bowen

Owner,Illume Cannabis Wellness

Session

Panel Moderator: Utilizing Cannabis as A Therapy for Chronic Pain

Round Table: Fair Market Value of Pain Creams

Cannabis

Ashley Robins

Ashley Robins

Ashley Robins, Marketing and Policy Lead, ANJA

Session

Regulatory Update: Hemp – 2018 US Farm Bill – Delta 8 THC,Delat 9 THC, Delta 10 THC
Panel: Discussion on Politics of Cannabis Treatment

Cannabis

Lauren Vrabel

Lauren Vrabel

Cannabis Pharmacist, Scientific Advisor, The Cannigma

Session

Round table: Adverse event reporting

Panel: Risks to Patients that Need to Be Considered

Cannabis

Cassandray	Gosa PharmD, MPH

Cassandray Gosa PharmD, MPH

Medical Cannabis Pharmacist, Founder, ChirpRX

Session

Panelist: Utilizing Cannabis as A Therapy for Chronic Pain Management

Round Table Moderator: 4th Year Rx Student APPE Clinical Rotation

 

Cannabis

Chad E. Burks, PharmD MBA MSMIT

Chad E. Burks, PharmD MBA MSMIT

VP, PIC, Westmoreland Clinical Services

Session

Panelist: Precision Medicine in Pharmacy: The Future of Clinical Management of Diseases

Round Table Moderator: Marketing – Getting Your Foot in The Door

 

Pharmacogenomics

Jeri Nichols, MS, PharmD, CGC

Jeri Nichols, MS, PharmD, CGC

GenePharmer, LLC

Session

Panelist: Precision Medicine in Pharmacy: The Future of Clinical Management of Diseases

Panelist: Emerging Trends in Pharmacogenomics

 

Growth and Entrepreneurship

Melissa Myers, CFP

Melissa Myers, CFP

Wealth Manager-Melissa Myers’ Team Kar-Mel Financial Planners

Session

Panelist:  How do you grow without a team?

Round Table: Financial planning for the future

Pharmacogenomics

Jena Quinn, PharmD, BCPPS

Jena Quinn, PharmD, BCPPS

Business Owner, Perfecting Peds

Session

Panelist: Why Be Entrepreneurs, Creating Subsidiaries and Alternative Revenue Streams

Round table moderator: Maternal and pediatric

Panel and round table moderator: Marketing

Pharmacogenomics

DeLon Canterbury, PharmD, BCGP

DeLon Canterbury, PharmD, BCGP

African American COVID-19 Task Force (AACT+) President/CEO of GeriatRx, Inc.

Session

Panel: Lets Talk To The Consultants To Consult About Being A Consultant

Panel: Opportunities (and challenges) To Whole Health Care Team Acceptance

Round Table: Specialized Populations - Geriatric

Growth and Entrepreneurship

Dr. Jerrica Dodd

Dr. Jerrica Dodd

Pharmacist Coach, Executive Editor PharmaSis Magazine

Session

Are you stuck?  Do you want to move forward in your life, become an entrepreneur, create new revenue streams for your business but find yourself unable to make any changes? Join Dr. Jerrica Dodd as she shares pearls and coaches on moving forward and building your dreams.

Panelist: How do you grow without a team?

Cannabis

Dr. Leah Johnson  PharmD, RPh

Dr. Leah Johnson PharmD, RPh

Medical Cannabis Consultant Pharmacist, Alchemist Consulting

Session

Regulatory Update: Hemp – 2018 US Farm Bill – Delta 8 THC, Delta 9 THC, Delta 10 THC

Panel: Utilizing Cannabis as A Therapy for Chronic Pain Management

Panel: Risks to Patients that Need to Be Considered

Round Table: Improving patient relationships with practitioners

Pharmacogenomics

Kevin Lazaruk RPh, BCGP, BCMAS

Kevin Lazaruk RPh, BCGP, BCMAS

LTC Consultant, Author

Session

Opportunities (And Challenges) To Whole Healthcare Team Acceptance

 Reviewing clinical data Is utilizing clinical judgment and looking at the overall patient

General, Cannabis, Pharmacogenomics

Dr. Thomas Kupiec

Dr. Thomas Kupiec

CEO, ARL Bio Pharma, Inc and DNA Solutions

Session

Regulatory Update: Hemp – 2018 US Farm Bill – Delta 8 THC, Delta 9 THC, Delta 10 THC

Panel: Emerging Trends in Pharmacogenomics

Precision Medicine and the future management of diseases

FDA Online - October 20

Ian Deveau

Ian Deveau

Deputy Office Director, FDA

Session

October 20, Virtual presentation and fireside chat

FDA Online - October 20

Gabrielle Cosel

Gabrielle Cosel

Director, Division of Compounding Policy and Outreach, Office of Compounding Quality and Compliance at FDA

Session

October 20, Virtual presentation and fireside chat

More Speakers To Be Announced

Compounding Pharmacies PodcastSign up for weekly alerts to latest episodes